Journal profile · Peripheral Vascular Disease

Atherosclerosis Supplements

ISSN 1567-5688 · eISSN 1878-5050 · Elsevier Ireland Ltd · IRELAND · Bimonthly · Founded 2000

Atherosclerosis Supplements: impact factor 2.09; hybrid open access; APC about USD 3,000; median 105 days to acceptance (98 articles, last 24 months); community-reported acceptance: moderate; 0 articles in 2025; indexed in Scopus.

Impact factor2.09Latest value listed by LetPub
CAS zone—Not in the CAS Journal Ranking
CiteScore quartileQ1Cardiology and Cardiovascular Medicine · rank 71/317 · 77th percentile
Review time105 daysMedian, submission to acceptance · 98 articles, last 24 months · PubMed
APCUSD 3,000Hybrid journal: charged only for open-access articles
AcceptanceModerateCommunity average
Articles per year02025 · OpenAlex count

Scope

Aims, scope and focus

Atherosclerosis Supplements is published by Elsevier Ireland Ltd. By OpenAlex counts of its recent articles, its largest topics are Lipoproteins and Cardiovascular Health, Cholesterol and Lipid Metabolism and Atherosclerosis and Cardiovascular Diseases, together about 45.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations.

Source: LetPub

Research area (LetPub): Peripheral Vascular Disease

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. Lipoproteins and Cardiovascular HealthMedicine20.4%
  2. Cholesterol and Lipid MetabolismMedicine13.5%
  3. Atherosclerosis and Cardiovascular DiseasesImmunology and Microbiology11.5%
  4. Diabetes, Cardiovascular Risks, and LipoproteinsMedicine8.2%
  5. Lipid metabolism and disordersMedicine6.8%
  6. Nitric Oxide and Endothelin EffectsMedicine4.1%
  7. Cardiovascular Health and Disease PreventionMedicine3.5%
  8. Paraoxonase enzyme and polymorphismsBiochemistry, Genetics and Molecular Biology3.5%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Not covered

Not covered by this edition.

CAS Xinrui Journal Ranking (March 2026)Not covered

Not covered by this edition.

CAS Journal Ranking, previous upgraded edition (December 2023)Not covered

Not covered by this edition.

CiteScore quartiles (Scopus, June 2026 release)

SubjectQuartileRankPercentile
Cardiology and Cardiovascular MedicineQ171/31777th
Internal MedicineQ237/12169th

Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub

Database indexing

ScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

Impact factor
2.09LetPub ·
CiteScore 2026-06
4.8LetPub ·
SJR 2026-06
0.69LetPub ·
SNIP 2026-06
0.6LetPub ·
h-index
46LetPub ·
h-index
62OpenAlex ·
i10-index
341OpenAlex ·
2-year mean citedness
0OpenAlex ·
Share of gold OA articles
34.15%LetPub ·

Articles by year OpenAlex count · 13,636 in total · the current year is incomplete

YearArticlesOpen accessCitations
202600316
202500510
202400746
202300816
202200876
2021001,075

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Review time from article dates manuscript dates registered with PubMed · to

105 daysMedian, submission to acceptance · P25–P75 60 days – 162 days

Acceptance to online
median 8 days (98 articles)
Submission to online
median 121 days
Sample
98 articles with submission and acceptance dates (557 in the window); the latest was accepted on

Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".

Other sources

Average review time (community reports)
over 12 weeksLetPub ·
Average acceptance (community reports)
ModerateLetPub ·

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Hybrid open accessLetPub

A subscription journal in which authors can pay to publish their article open access.

SourceAPCFee waiverLicenseObserved
OpenAlexUSD 3,000——

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Profile

Publication details and official links

Publisher
Elsevier Ireland Ltd
Country or region
IRELAND
Language
English
Frequency
Bimonthly
Founded
2000
ISSN
1567-5688
Electronic ISSN
1878-5050
Official links

FAQ

Frequently asked questions about Atherosclerosis Supplements

What is the impact factor of Atherosclerosis Supplements?

The latest impact factor listed by LetPub is 2.09; CiteScore 4.8, h-index 62.

How long does peer review take at Atherosclerosis Supplements?

Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 105 days (interquartile range 60–162 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

Which databases index Atherosclerosis Supplements?

According to LetPub and DOAJ records, Atherosclerosis Supplements is indexed in Scopus.

Is Atherosclerosis Supplements open access, and what is the APC?

Atherosclerosis Supplements is a hybrid journal. For open-access publication: APC about USD 3,000.

Sources and updates

The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .